Company Description
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.
In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma.
The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 152 |
| CEO | Brent Pfeiffenberger M.B.A., Pharm.D. |
Contact Details
Address: 25 N 38th Street, 11th Floor Philadelphia, Pennsylvania 19104 United States | |
| Phone | 215-981-4000 |
| Website | centurytx.com |
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001850119 |
| CUSIP Number | 15673T100 |
| ISIN Number | US15673T1007 |
| Employer ID | 84-2040295 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Brent Pfeiffenberger M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Dr. Adrienne Farid Ph.D. | Chief Operating Officer and Head of Early Development |
| Douglas Carr CPA | Interim Principal Financial Officer, Senior Vice President of Finance and Operations and Secretary |
| Dr. Gregory Russotti Ph.D. | Chief Technology and Manufacturing Officer |
| Kenneth J. Dow J.D. | Senior Vice President of General Counsel |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Dr. Hyam I. Levitsky M.D. | President of Research and Development |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering |
| Dr. Nick Trede M.D., Ph.D. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | EFFECT | Notice of Effectiveness |
| Jun 26, 2024 | 8-K/A | [Amend] Current report |
| Jun 26, 2024 | 424B3 | Prospectus |
| Jun 24, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 144 | Filing |
| Jun 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 5, 2024 | 144 | Filing |
| Jun 3, 2024 | 8-K | Current Report |
| May 22, 2024 | 424B3 | Prospectus |
| May 21, 2024 | EFFECT | Notice of Effectiveness |